about
Common variation in the LRRK2 gene is a risk factor for Parkinson's disease.Diagnostic agreement in patients with psychogenic movement disordersNovel Lrrk2-p.S1761R mutation is not a common cause of Parkinson's disease in Spain.Motivational modulation of bradykinesia in Parkinson's disease off and on dopaminergic medication.Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study.Practical guidance for CD management involving treatment of botulinum toxin: a consensus statement.Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study.GDNF gene is associated with tourette syndrome in a family studyConsensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study).Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert.The social impact of Parkinson's disease in Spain: Report by the Spanish Foundation for the Brain.Advanced Parkinson's disease: clinical characteristics and treatment. Part II.Tics and other stereotyped movements as side effects of pharmacological treatment.Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease.Study of cerebello-thalamocortical pathway by transcranial magnetic stimulation in Parkinson's disease.Statuslike SUNCT in two young women.Low serum uric acid concentration in Parkinson's disease in southern Spain.Mitochondrial DNA A4336G mutation in Alzheimer's and Parkinson's diseases.Genome-wide association study in musician's dystonia: a risk variant at the arylsulfatase G locus?[Advanced Parkinson's disease: clinical characteristics and treatment (part 1)].Changes in intracortical circuits of the human motor cortex following theta burst stimulation of the lateral cerebellum.Abnormal sensorimotor plasticity in CADASIL correlates with neuropsychological impairment.Prophylactic treatment of episodic cluster headache with intravenous bolus of methylprednisolone.International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease.Abnormal cortical and spinal inhibition in paroxysmal kinesigenic dyskinesia.Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease.Secondary generalized dystonia without basal ganglia damage.Abnormal GABA-mediated and cerebellar inhibition in women with the fragile X premutation.Effects of two weeks of cerebellar theta burst stimulation in cervical dystonia patients.Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families.Cluster headache with aura.Analysis of c.801-2A>G mutation in the DNAJC6 gene in Parkinson's disease in southern Spain.Cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in Parkinson disease.Machine learning models for the differential diagnosis of vascular parkinsonism and Parkinson's disease using [(123)I]FP-CIT SPECT.Genetic variability related to serum uric acid concentration and risk of Parkinson's disease.Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients.Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs).Glucose-6-phosphate dehydrogenase activity in Parkinson's disease.N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.Dopaminergic drugs restore facilitatory premotor-motor interactions in Parkinson disease.
P50
Q30531323-91FC94D4-6B61-4F55-9A45-2C149392DE67Q30540412-7D0EA241-105D-4DF9-8AE2-A92C33C537AAQ30540754-10AD525B-0261-4987-B940-CF5FEF0CC2CEQ33755328-542C29BA-DDCE-48D2-ADAD-546D94205F4FQ34376763-A1D90064-CF30-4524-B417-F0E379908C96Q36171693-BE0851A0-A9A8-432F-BEBC-2B4229B35394Q36227173-694333CB-2F13-4959-93AE-92D3DEACC7DCQ37282946-566612EA-28AE-4EAF-A82B-8897E9619261Q37625315-707724DF-C0BA-405B-9B77-3B7D9EA79876Q37978131-6EB6C2AE-F9C2-469C-A624-3BDA3C606E15Q38118460-A52B9546-AA30-4692-8D34-6D91D1E834DEQ38123595-6A53F624-095E-4914-A5E9-4B3195A92B00Q38167917-2647A3C4-132A-47F6-AA0C-D3C577732859Q43253701-AC75FFB4-E35C-455C-8398-0D17AE242E53Q43444128-5338822C-8144-4AB2-95CC-8C46A822DA25Q43750265-71653948-D131-4AF1-B34E-CFF00370322AQ44003807-43C3C71E-CB1F-40A4-86F1-1472FA373899Q44077480-8D838E8D-2637-4E11-90EB-232BF687668BQ44248875-A101F061-635F-4629-98B6-8434328648F8Q44369145-F328147B-83A5-48C8-89EF-7CB72A3F8ED2Q44572048-FD4A478E-A9B4-4C03-B04F-1DB352EBB0A3Q44710058-C9E46550-FD40-40D1-8450-91ACC1604193Q44723682-9D0591EB-D6D5-412F-9FD2-2D5F20DE19F4Q44922957-A166C3FD-C488-442F-A147-7D26A234C7DDQ45200722-5B4D0919-FB11-4BE2-A41A-8606556E95C4Q45246047-4D91AC13-084A-4107-9974-92D4EC58AB6DQ45285179-3D3091E5-F4AA-4E55-989B-CF24C1262E44Q45399687-DBB0E459-73A1-4972-9E85-9617B4BFEE82Q45768307-79621D8F-BDF6-4FA7-8768-6DD20D677C4BQ45771551-3CE51E50-A8DA-43C5-8293-37248C1CC050Q45908994-CA4C0A3F-A4C0-4749-9FF8-813D6E42A54CQ45929748-A0C236F6-C1C1-455B-B00D-65125C78A311Q45930045-AEA71F79-38FD-465A-8B81-F2E9236AD204Q45956473-5CCEFEAB-2DC8-46CA-A180-FD490AB278EFQ45980386-0761B694-056E-4592-9A28-5FC9204CB990Q46068727-75ED998D-5691-45CD-8EFB-D9219B394686Q46093174-459DDDA6-C1B9-4680-9F69-07FB79BC76ADQ46155323-984CB5F9-B8DD-4DB6-A78C-F61801920AF2Q46325430-DAAD19BC-7B65-49F0-B595-FAD18FFFBFCDQ46546789-4B17A7E7-09A6-46EF-8E44-DF824407B2DC
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pablo Mir
@ast
Pablo Mir
@en
Pablo Mir
@es
Pablo Mir
@nl
Pablo Mir
@sl
type
label
Pablo Mir
@ast
Pablo Mir
@en
Pablo Mir
@es
Pablo Mir
@nl
Pablo Mir
@sl
altLabel
P Mir
@en
prefLabel
Pablo Mir
@ast
Pablo Mir
@en
Pablo Mir
@es
Pablo Mir
@nl
Pablo Mir
@sl
P1053
C-8662-2013
P106
P1153
14060780400
P21
P31
P3829
P4012
P496
0000-0003-1656-302X